350 rub
Journal №8 for 2013 г.
Article in number:
Antibiotic activity of the rifabutin nanoparticle formulation
Keywords: rifabutin polymer nanoparticles lungs tuberculosis
Authors:
I.G. Kuznetsova, E.A. Voroncov, S.L. Kuznetsov, G.G. Barsegyan, S.E. Severin
Abstract:
The article is devoted to the actual problem of the creation of high-performance, low-toxic anti-tuberculosis drugs that can overcome the acquired drug resistance. The article provides a description of nanoparticle antibiotic rifabutin, that is used for resistant tuberculosis, formulation receipt. The resulting comparative evaluation of the antimicrobial nanosomal activity of established pharmaceutical form and free substance showed a significant increase in the efficiency of the developed drug. The attention is paid to the necessity of a search for effective methods to increase the effectiveness of pharmaceuticals, capable to accelerate fight against tuberculosis at the source of infection.
Pages: 48-52
References

  1. Dhople A.M., Ibanes M.A. In vitro activity of three new fluoroqinolones and synergy with ansamycins against Mycobacterium leprae // J. Antimicrob Chemother. 1993. V. 32. R. 445-449.
  2. Francis J. Drug-resistand Tuberculosis: a survival guide for clinicias / San Francisco, Curry National Tuberculosis Center and California Department of Health Services. 2004.
  3. Moghimi S. M., Hunter A.C., Murrey J.C. Long-circulating and targetspecific nanoparticles: theory to practice // Pharmacol. Rev. 2001. V. 53. P. 283-318.
  4. Monography. Mycobutin, rifabutin capsules, USP
  5. National Committee for Clinical Laboratory Standards.  Performance Standards for antimicrobial susceptibility testing 13th and 14th informational supplement. NCCLS document M100-S13.2003 and document M100-S14. 2004. Wayne, PA.
  6. National Committee for Clinical Laboratory Standards. 1997. Method for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved Standard M-7-A4 / 4th ed. Villanova.
  7. Shafran S., Deschenes J., Miller M. et al. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol // N Engl J. Med. 1994. V. 330. P. 438-439.
  8. Kukushkin Ju.N. Dimetilsul'foksid ? vazhnejshij aprotonny'j rastvoritel' // Sorosovskij obrazovatel'ny'j zhurnal. 1997. № 9. S. 54-56.
  9. Opredelenie chuvstvitel'nosti mikroorganizmov k antibakterial'ny'm preparatam. Metodicheskie ukazaniya. MUK 4.2.1890-04. 2004.
  10. Hillaireau H., Couvreur P. Nanocarriers? entry into the cell: relevance to drug delivery // Cellular and Molecular Life Sciences. 2009. V.66. P. 2873-2896.
  11. Patent № 2327457 (RF). Lekarstvennoe sredstvo na osnove rifabutina, preparat protivomikrobnogo dejstviya, soderzhashhij nanochasticzy', i sposob ego polucheniya / E.S. Severin, L.N. Kryukov, I.E. Zy'kova, G.G. Barsogyan, E.A. Voronczov, S.L. Kuzneczov, T.A. Pomazkova, S.G. Gumakov.
  12. Pul Ch., Oue'ns F. Mir materialov i texnologij. Nanotexnologii. M.: Texnosfera. 2006. S. 319-327.
  13. Shtil'man M.I. Polimery' mediko-biologicheskogo naznacheniya. M.: Akademkniga. 2006. 400 s.
  14. Klimova O.V., Voronczov E.A., Semenov S.Ju., Severin S.E., Severin E.S. Vliyanie nekotory'x parametrov sinteza na svojstva nanosomal'noj lekarstvennoj formy', poluchaemoj na osnove sopolimerov molochnoj i glikolevoj kislot // Voprosy' biologicheskoj, mediczinskoj i farmaczevticheskoj ximii. 2010. № 4. S. 27-33.